Search results
Showing 31 to 45 of 74 results for cystic fibrosis
Living-donor lung transplantation for end-stage lung disease (HTG111)
Evidence-based recommendations on living-donor lung transplantation for end-stage lung disease. This involves removing a lung from each of the two donors and replacing the recipient's lungs with the donor lungs.
View recommendations for HTG111Show all sections
Sections for HTG111
Evidence-based recommendations on ex-situ machine perfusion for extracorporeal preservation of lungs for transplant. This involves using a machine to deliver an oxygenated solution to a donor lung and keep it at normal body temperature until it can be transplanted.
View recommendations for HTG580Show all sections
Liver disease:- Should all children with meconium ileus receive ursodeoxycholic acid from diagnosis?
of mortality in people with cystic fibrosis, and around 10 to 30% of people with cystic fibrosis will develop...
Discontinued Reference number: GID-TA10277
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with cystic fibrosis see our guideline on diagnosing and managing cystic fibrosis and for people with COVID-19 see our guideline on managing COVID-19.
Discontinued Reference number: GID-TA10566
Ataluren for treating cystic fibrosis in people with a CFTR gene nonsense mutation [ID955]
Discontinued Reference number: GID-TA11262
This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.
Discontinued Reference number: GID-TA10390
from guidance Mannitol dry powder for inhalation for treating cystic fibrosis Number TA266 Date issued November 2012 Other
Faltering growth: recognition and management of faltering growth in children (NG75)
This guideline covers recognition, assessment and monitoring of faltering growth in infants and children. It includes a definition of growth thresholds for concern and identifying the risk factors for, and possible causes of, faltering growth. It also covers interventions, when to refer, service design, and information and support.
Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)
Evidence-based recommendations on hybrid closed loop systems for managing blood glucose levels in type 1 diabetes.
Highly specialised technologies evaluation committee members
Biographies for each member of the highly specialised technologies evaluation committee.
Highly specialised technologies evaluation committee members
Biographies for each member of the highly specialised technologies evaluation committee.